荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

休市中 06-12 16:08:21

74.550

+4.900

+7.04%

最高76.400	最低68.350	成交量781.57万
今开70.750	昨收69.650	日振幅11.56%
总市值420.17亿	流通市值155.50亿	总股本5.64亿
成交额5.73亿	换手率3.75%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":74.55,"timestamp":1781251701012,"preClose":69.65,"halted":0,"volume":7815688,"delay":0,"changeRate":0.07035175879396972,"floatShares":208581239,"shares":563608243,"eps":1.4945870193776885,"marketStatus":"休市中","change":4.9,"latestTime":"06-12 16:08:21","open":70.75,"high":76.4,"low":68.35,"amount":573388489,"amplitude":0.115578,"askPrice":74.6,"askSize":2500,"bidPrice":74.55,"bidSize":13000,"shortable":3,"etf":0,"ttmEps":2.7046208905901064,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":7,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":69.65,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":1.987166,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":113.9,"timestamp":1781247600000,"preClose":105.19,"halted":0,"volume":15766000,"delay":0,"premium":"-43.51"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"2642430261","title":"荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2642430261","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642430261?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:45","pubTimestamp":1781257538,"startTime":"0","endTime":"0","summary":"证券之星消息，荣昌生物(688331)06月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司近年是否存在向欧盟成员国出口或销售的相关业务？如有，欧盟地区业务收入在公司整体营业收入中的占比大致为多少？此外，公司对欧盟市场的销售主要通过哪种方式实现：是以境内主体直接向欧盟客户出口为主，还是通过在欧盟国家设立的子公司进行销售，或通过第三方贸易商、代理商转销至欧盟市场？荣昌生物回复：尊敬的投资者您好，公司尚无药品在欧盟获批上市，无药品向欧盟出口销售，未来业务的开展情况，还请您关注公司的相关公告，感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200028056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","LU2148510915.USD","FESXmain","FSXEmain","BK1161","LU2328871848.SGD","09995","LU1064130708.USD","BK1574","LU1064131003.USD","BK0239","BK1583","LU1969619763.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642261142","title":"荣昌生物：辉瑞会计处理不会影响合作权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2642261142","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642261142?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:45","pubTimestamp":1781257523,"startTime":"0","endTime":"0","summary":"公司与辉瑞就维迪西妥单抗合作的里程碑付款及销售分成等权益，均由双方签署的协议条款所约定，辉瑞方面的相关会计处理不会影响上述合作权益。目前辉瑞正在推进的临床试验进展，还请关注合作伙伴的官方披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200028042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","LU2148510915.USD","BK0239","LU1064130708.USD","BK1583","LU1969619763.USD","LU2488822045.USD","09995","BK1161","BK1574","LU1064131003.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642659282","title":"荣昌生物涨8.28%，东海证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642659282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642659282?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:29","pubTimestamp":1781252941,"startTime":"0","endTime":"0","summary":"今日荣昌生物涨8.28%，收盘报113.9元。2026年4月3日，东海证券研究员杜永宏,付婷发布了对荣昌生物的研报《公司简评报告：商业化+BD驱动高增长，创新研发快速推进》，该研报对荣昌生物给出“买入”评级。公司经营效率不断提升，国际化进程加速，维持“买入”评级。荣昌生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200025375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","161027","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642257792","title":"港股异动 | 创新药概念多数走高 行业BD交易延续高景气 政策支持与商业化盈利兑现逻辑不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2642257792","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642257792?lang=zh_cn&edition=full","pubTime":"2026-06-12 14:50","pubTimestamp":1781247029,"startTime":"0","endTime":"0","summary":"消息面上，今年一季度，中国创新药对外授权交易总额突破600亿美元，显示出海已从“偶发大单”升级为可持续的产业能力；另一方面，ASCO 2026中国研究入选数量和学术层级也在继续提升。近期多个创新药数据读出，重要BD陆续公告，事件性催化不断；中国创新药全球竞争力持续加强，政策支持与商业化盈利兑现的产业逻辑不变。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","01276","BK1191","LU1023057109.AUD","BK1161","BK4588","LU1969619763.USD","BK1583","06990","LU2328871848.SGD","LU2543165471.USD","09995","LU0196878994.USD","LU0359201612.USD","BK1574","LU0359201885.HKD","VXUS","LU0359202008.SGD","BK4585","159992","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642254781","title":"医药板块集体回升 科伦博泰生物(06990)涨7.20%、荣昌生物(09995)涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642254781","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642254781?lang=zh_cn&edition=full","pubTime":"2026-06-12 13:30","pubTimestamp":1781242214,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药板块集体回升，科伦博泰生物 涨7.20%，荣昌生物涨6.53%，康诺亚-B涨5.58%，复宏汉霖涨5.36%，康方生物涨5.07%，君实生物涨4.61%，药明合联涨4.06%，诺诚健华涨3.96%。英伟达同时为 Abridge 投资方，新模型基于英伟达开放模型套件 Nemotron 训练，Abridge 将采用去标识化临床数据进行定制优化，预计 2026 年晚些时候上线。东莞证券研报认为，受行业合规整顿以及消费疲软等因素影响，2025年医药生物行业整体归母净利润同比有所下滑。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983673","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","LU2488822045.USD","HK0000165453.HKD","06990","LU0348784397.USD","688331","HK0000320264.USD","LU2476274720.SGD","01877","LU2476274308.USD","LU2148510915.USD","LU1064131003.USD","HK0000320223.HKD","LU0348827113.USD","BK1574","LU1064130708.USD","LU2399975544.HKD","LU0348766576.USD","LU0417516902.SGD","SG9999014674.SGD","09995","BK1583","LU0417516738.SGD","IE00BPRC5H50.USD","BK1161","LU0540923850.HKD","LU1961090484.USD","LU0561508036.HKD","LU1720050803.USD","LU0348767384.USD","LU1794554557.SGD","BK0239","LU0348825331.USD","09926","BK1141","LU2328871848.SGD","LU0348735423.USD","LU0348783233.USD","159938","09939","09969","BK1587","HK0000306701.USD","02162","02696","BK1515","LU0417516571.SGD","02268","LU1969619763.USD","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642463933","title":"荣昌生物涨5.07%，东海证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2642463933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642463933?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:42","pubTimestamp":1780994575,"startTime":"0","endTime":"0","summary":"今日荣昌生物涨5.07%，收盘报102.41元。2026年4月3日，东海证券研究员杜永宏,付婷发布了对荣昌生物的研报《公司简评报告：商业化+BD驱动高增长，创新研发快速推进》，该研报对荣昌生物给出“买入”评级。公司经营效率不断提升，国际化进程加速，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为23.03%。荣昌生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688331","09995","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642783455","title":"港股异动 | 荣昌生物(09995)盘中涨超5%泰它西普两大适应症同日获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2642783455","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642783455?lang=zh_cn&edition=full","pubTime":"2026-06-09 10:29","pubTimestamp":1780972163,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物(09995)盘中涨超5%，截至发稿，涨3.78%，报71.3港元，成交额2.58亿港元。消息面上，6月8日，荣昌生物宣布，公司自主研发的全球首创BLyS/APRIL双靶点融合蛋白创新药泰它西普（RC18）治疗干燥综合征（干燥病）、IgA肾病的两项新适应症获国家药品监督管理局（NMPA）批准上市，标志着干燥综合征领域迎来了全球首个获批的生物制剂，同时开启了精准治疗IgA肾病新时代。至此，泰它西普已有系统性红斑狼疮、类风湿关节炎、全身型重症肌无力、干燥综合征（干燥病）、IgA肾病等五个适应症在国内获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU2328871848.SGD","BK1161","688331","BK4588","LU2148510915.USD","BK1574","VXUS","BK1583","BK4585","LU1969619763.USD","LU1064131003.USD","LU1064130708.USD","LU2488822045.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186535086","title":"异动解读｜荣昌生物盘中上涨5.68%，核心产品泰它西普两项新适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1186535086","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186535086?lang=zh_cn&edition=full","pubTime":"2026-06-09 10:24","pubTimestamp":1780971893,"startTime":"0","endTime":"0","summary":"6月9日，荣昌生物盘中上涨5.68%，报72.6港元/股，成交额2.28亿港元。消息面上，公司公告核心产品泰它西普（泰爱）新获两项适应症上市批准：注射用泰它西普治疗干燥综合征获批，同日泰它西普注射液治疗IgA肾病通过优先审评审批获附条件批准上市。泰它西普为全球首个BLyS/APRIL双靶点创新药，干燥综合征III期研究为全球该领域首个获得强阳性结果的双靶点生物制剂项目；IgA肾病III期数据已发表于《新英格兰医学杂志》，临床价值获权威认可。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641485599","title":"荣昌生物：注射用泰它西普治疗干燥综合征上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2641485599","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641485599?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:22","pubTimestamp":1780914120,"startTime":"0","endTime":"0","summary":"6月8日，荣昌生物（688331/09995）发布公告，公司收到国家药品监督管理局核准签发的药品注册证书，注射用泰它西普治疗干燥综合征（干燥病）的新适应症上市申请获批。泰它西普是公司自主研发的全球首个BLyS/APRIL双靶点创新药，通过同时抑制BLyS和APRIL与B细胞表面受体结合，阻断B细胞异常分化和成熟，更好地控制疾病活动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606083763744625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","LU1969619763.USD","LU1064131003.USD","BK1161","BK1583","LU2488822045.USD","09995","688331","LU2328871848.SGD","LU2148510915.USD","LU1064130708.USD","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152558436","title":"荣昌生物发布2026年5月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1152558436","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152558436?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:43","pubTimestamp":1780562598,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司于2026年6月4日披露截至2026年5月31日的股份变动月报表。公告显示，公司本月未发生新增发行、购买、注销或转让库存股份等情况，股本结构保持稳定。根据月报，荣昌生物制药（烟台）股份有限公司的注册股本合计为人民币564,477,483元，本月未发生变动。两类股份的已发行及未发行股份数目均无新增或减少情形，总股本保持在564,477,483股。本次公告由公司董事王威东签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174198904","title":"荣昌生物4月股份变动月报表：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1174198904","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174198904?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:36","pubTimestamp":1780562211,"startTime":"0","endTime":"0","summary":"2026年6月4日，荣昌生物制药（烟台）股份有限公司披露截至2026年4月30日的股份变动月报表。报告显示，报告期内公司无新增发行、购回或注销股份活动，总股本保持稳定。根据公告，截至2026年4月末，荣昌生物制药（烟台）股份有限公司法定/注册股本合计为人民币564,477,483元，普通股分为H股与A股两类，面值均为每股人民币1元。公司表示，截至2026年4月30日，其H股公众持股量符合香港联交所《上市规则》所规定的最低要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145352251","title":"异动解读 | 中美监管壁垒抬升压制估值，荣昌生物盘中大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145352251","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145352251?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:08","pubTimestamp":1780463339,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中股价大跌5.02%，引发市场关注。消息面上，股价下跌主要受中美生物科技领域监管环境变化影响。美国议员近期提议将生物技术纳入COINS法案管制范畴，旨在限制美资流入中国创新药企。同时，市场传闻国内拟对创新药海外授权（BD）交易增设前置审批。中美双向监管壁垒的同步抬升，直接冲击了创新药板块的出海逻辑与估值核心。此外，东方证券此前减持了荣昌生物16万股，ETF资金也呈现持续净流出态势，板块整体承压，同行业个股普遍下跌。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145134300","title":"异动解读｜荣昌生物盘中下跌5.02%，中美生物科技双向监管壁垒抬升持续压制创新药出海估值","url":"https://stock-news.laohu8.com/highlight/detail?id=1145134300","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145134300?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:08","pubTimestamp":1780463280,"startTime":"0","endTime":"0","summary":"6月3日，荣昌生物盘中下跌5.02%，报72.85港元/股，成交额1.57亿港元，延续近期弱势走势。消息面上，美国议员近期提议将生物技术纳入COINS法案管制范畴，限制美资流入中国创新药企；同时市场传闻国内拟对创新药海外BD交易增设前置审批，中美双向监管壁垒同步抬升，直接冲击板块估值核心逻辑。此外，东方证券此前减持荣昌生物16万股，ETF资金持续净流出，板块整体承压。同行业个股普跌，康方生物跌3.1%、三生制药跌4.03%、信达生物跌2.92%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640932958","title":"荣昌生物(09995)拟以3亿元的闲置自有资金向浦发银行烟台分行购买理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2640932958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640932958?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:46","pubTimestamp":1780303573,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，于2026年6月1日，本公司进一步与浦发银行烟台分行订立浦发银行理财产品8号协议，据此本公司同意以人民币3亿元的闲置自有资金向浦发银行烟台分行购买理财产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0187","LU1064131003.USD","688331","600000","BK1161","BK1583","LU2328871848.SGD","BK0086","LU2148510915.USD","LU2488822045.USD","LU1934453819.USD","BK1574","LU0469268626.HKD","09995","BK0201","LU1064130708.USD","BK0278","BK0188","LU1969619763.USD","LU1979443071.USD","BK0239","BK0012","BK0015","SGXZ49509284.SGD","BK0183","SGXZ81163826.USD","LU1808992512.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139932624","title":"异动解读 | 监管施压与机构减持双重打击，荣昌生物盘中大跌5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139932624","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139932624?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:37","pubTimestamp":1780285036,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中股价出现大幅下跌，跌幅达5.38%，市场关注度迅速升温。消息面上，多重因素共同导致了此次股价承压。同时，市场传闻国内监管机构拟对创新药企的海外业务发展交易增设前置审批，中美双向监管壁垒的抬升，直接冲击了板块的估值逻辑。此外，具体到公司层面，东方证券近期减持了荣昌生物16万股，同时相关ETF资金也出现连续多日的净流出。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112935446","title":"异动解读｜荣昌生物盘中下跌5.08%，中美生物科技博弈升级叠加创新药板块持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1112935446","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112935446?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:10","pubTimestamp":1780283414,"startTime":"0","endTime":"0","summary":"6月1日，荣昌生物盘中下跌5.08%，报78.45港元/股，成交额3.05亿港元。消息面上，美国议员近期提议将生物技术纳入COINS法案管制范畴，限制美国资本流入中国创新药企，叠加市场传闻国内拟对创新药海外BD交易增设前置审批，双向监管壁垒抬升令板块估值逻辑承压。此外，东方证券近期减持荣昌生物16万股，ETF资金连续多日净流出，行业整体面临资金转向AI等赛道的风格切换阵痛，创新药出海预期受挫成为压制估值的核心因素。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639628589","title":"荣昌生物涨6.50%，东海证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2639628589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639628589?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:38","pubTimestamp":1780043890,"startTime":"0","endTime":"0","summary":"今日荣昌生物涨6.50%，收盘报116.03元。2026年4月3日，东海证券研究员杜永宏,付婷发布了对荣昌生物的研报《公司简评报告：商业化+BD驱动高增长，创新研发快速推进》，该研报对荣昌生物给出“买入”评级。公司经营效率不断提升，国际化进程加速，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为23.03%。荣昌生物个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900030222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","688331","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131429732","title":"港股异动｜创新药概念股拉升，信达生物涨近13%，石药集团、荣昌生物涨7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131429732","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131429732?lang=zh_cn&edition=full","pubTime":"2026-05-29 13:44","pubTimestamp":1780033481,"startTime":"0","endTime":"0","summary":"诺诚健华涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"14627b4c07acfccfc4c1fb81226a69da","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","01093","09969","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106293009","title":"异动解读｜荣昌生物盘中上涨5.13%，泰它西普新适应症临床推进叠加板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1106293009","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106293009?lang=zh_cn&edition=full","pubTime":"2026-05-29 13:32","pubTimestamp":1780032729,"startTime":"0","endTime":"0","summary":"5月29日，荣昌生物盘中上涨5.13%，报83.0港元/股，成交额2.42亿港元。此前泰它西普治疗IgA肾病的Ⅲ期临床结果已登上《新英格兰医学杂志》，临床管线持续兑现。荣昌生物是一家专注于抗体药物偶联物、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域的生物医药公司，主要产品包括泰它西普、维迪西妥单抗等，应用于自身免疫疾病、肿瘤及眼科疾病领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638197575","title":"东方证券减持荣昌生物(09995)16万股 每股均价约84.83港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638197575","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638197575?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:30","pubTimestamp":1779795004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月19日，东方证券减持荣昌生物(09995)16万股，每股均价84.8306港元，总金额约为1357.29万港元。减持后最新持股数目为1037.45万股，最新持股比例为4.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1064130708.USD","LU1969619763.USD","EWH","BK1564","BK0028","BK0183","LU2488822045.USD","LU1064131003.USD","03958","BK0276","688331","BK1583","LU2148510915.USD","09995","BK1147","BK0188","LU2328871848.SGD","BK1574","BK1161","600958","BK0012"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0574},{"period":"1month","weight":-0.1941},{"period":"3month","weight":-0.1605},{"period":"6month","weight":-0.0563},{"period":"1year","weight":0.2931},{"period":"ytd","weight":0.0354}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.110172},{"month":2,"riseRate":0.666667,"avgChangeRate":0.167223},{"month":3,"riseRate":0.5,"avgChangeRate":0.012545},{"month":4,"riseRate":0.833333,"avgChangeRate":0.095268},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.049233},{"month":6,"riseRate":0.666667,"avgChangeRate":0.09013},{"month":7,"riseRate":0.6,"avgChangeRate":-0.032319},{"month":8,"riseRate":0.4,"avgChangeRate":0.068611},{"month":9,"riseRate":0.6,"avgChangeRate":0.099222},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}